This is a promotional website with content intended for UK healthcare professionals only

Cessation of visible signs of seizures within 10 min has been observed in the majority of children 1-3

Simple and socially acceptable buccal route of administration 2-5

BE PREPARED WHEN SEIZURES STRIKE
BUCCOLAM is indicated for the treatment of prolonged, acute, convulsive seizures in adults, adolescents, children and infants aged 3 months and above. BUCCOLAM must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.1

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions. UK reporting forms and information can be found via the Yellow Card Scheme www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Stores. Adverse events should also be reported to Neuraxpharm UK Ltd by emailing pv-uk@neuraxpharm.com

Looking for an educational resource on BUCCOLAM®?

Sign up to webinar updates!

References
1. Buccolam 2.5 mg , 5 mg, 7.5 mg and 10 mg Summaries of Product Characteristics
2 McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005 Jul 16-22;366(9481):205-10. doi: 10.1016/S0140-6736(05)66909-7. PMID: 16023510.
3 Mpimbaza A, Ndeezi G, Staedke S, et al. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics. 2008 Jan;121(1):e58-64. doi: 10.1542/peds.2007-0930. PMID: 18166545. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible, and resuscitation equipment is available.
4 Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev. 2009 Nov;31(10):744-9. doi: 10.1016/j.braindev.2008.11.006. Epub 2008 Dec 27. PMID: 19114297.
5 Ashrafi MR, Khosroshahi N, Karimi P, et al. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. Eur J Paediatr Neurol. 2010 Sep;14(5):434-8. doi: 10.1016/j.ejpn.2010.05.009. Epub 2010 Jun 15. PMID: 20554464.

This information is intended for use by healthcare professionals.

NXUK/E/1125/01 December 2025

Please confirm your status

The content of this website is for the exclusive use of healthcare professionals authorised to prescribe, dispense, indicate, use or authorise the dispensing of prescription medicines in United Kingdom.

Click Accept if you are a healthcare professional in United Kingdom and wish to continue on this site or Exit to be redirected to the Neuraxpharm United Kingdom website.